explore -WSS

explore

author：explore 2025-09-30 17:59:33 - browse：556

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Palantir health business leans on meeting customers’ needs

WSS

Study: Pain burden is higher in Black NFL players than white ones

Elizabeth Holmes on track for early release from her 11

Christmas in the PICU brings some surprising joy

New research casts further doubt on a common procedure used with IVF

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Carvykti CAR

focus

explore

leisure time

Drug repurposing or repositioning? The language matters

Oak trusses raised to roof of fire

Peter Hotez and the public health issue of online harassment

Lecanemab for Alzheimer's is coming. Is the health system ready?

Hepatitis C has a cure — but many Americans still lack access to it

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Walensky prepares to leave CDC — and Congress — behind

SEC charges former device maker CEO with $41 million fraud

Moonlake's readout produced a cash windfall. Risks remain

Study: Pain burden is higher in Black NFL players than white ones

knowledge

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Why health care costs have stayed mostly flat since 2010

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Lecanemab for Alzheimer's is coming. Is the health system ready?

Virtual care provider acquires bankrupt Pear's prescription apps

How to keep neuroscience’s past racism from being its future

focus

hotspot

Wikipedia

knowledge